SELECT THERAPEUTICS WKN 937075
Könnten bald mit interessanten News kommen, aktuell 0,14$ in USA, auf freerealtime.com unter Kürzel: xzl bereits
0,19$zu sehen!!!
In Berlin wird schon zu 0,2€. getaxt, Frankfurt taxt 0,15€. im ask, es gibt aber dafür leider scheinbar keine...
Letzte Meldung schon sehr positiv:
Select Therapeutics Inc. Receives Notification of American Stock Exchange Acceptance of Plan of Compliance
BOSTON, Aug 1, 2002 /PRNewswire-FirstCall via COMTEX/ -- Select Therapeutics
Inc. (Amex: XZL), today announced that the American Stock Exchange ("AMEX" or
the "Exchange" has accepted Select`s plan of compliance and that the Company
has received a listing extension to regain compliance with AMEX`s listing
standards on or before December 31, 2003, subject to periodic review by the
Exchange.
On April 26, 2002, Select received notice from the AMEX Staff indicating that,
as of the date of the letter, the Company had fallen below the continued
listings standards of the Exchange due to stockholders equity below $2 million
dollars and sustained losses in two of its most recent fiscal years, as set
forth in Section 1003(a) of the AMEX Company Guide. Select was afforded the
opportunity to submit a plan of compliance to the Exchange and on May 28, 2002
the Company presented its plan to the Exchange. On July 26, 2002, the Exchange
notified Select that it accepted the Company`s plan of compliance and granted
the Company an extension of time to regain compliance with the continued listing
standards. Select will be subject to periodic review by Exchange Staff during
the extension period. Failure to make progress consistent with the plan or to
regain compliance with the continued listing standards by the end of the
extension period could result in the Company being delisted from the American
Stock Exchange.
"We are pleased to have received this notice of extension from AMEX," said Craig
Sibley, President and CEO. "This is another positive step forward in returning
Select to a stable and progressive status."
About Select:
Select Therapeutics Inc. is a drug development company engaged in the
development of novel, targeted therapeutic entities for the treatment of cancers
and infectious diseases. The Company is developing its proprietary, targeted
cancer therapeutic agent, VeroPulse(TM), for the treatment of certain cancers,
and also its proprietary targeted therapeutic vaccine technologies (Activate(TM)
and VeroVax(TM) for the treatment of cancers and infectious diseases. In
December 2001, Select Therapeutics Inc. terminated its joint venture, Cell
Science Therapeutics, and resumed an independent path for corporate and
technological development.
Certain of the statements contained in this news release may be considered
forward-looking statements. To the extent that any of the statements contained
herein are forward-looking, such statements are based on current expectations
and are subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. We caution investors that there can be no assurance that actual
results or business conditions will not differ materially from those projected
or suggested in such forward-looking statements as a result of various factors,
including, but not limited to, Select`s need for and ability to obtain
additional capital, the possible impairment of, or inability to obtain,
intellectual property rights and the cost of obtaining such rights from third
parties and dependence on third parties to research, develop, manufacture and
sell any products developed.
Was denkt Ihr?
MfG
Star Ikone 2
Könnten bald mit interessanten News kommen, aktuell 0,14$ in USA, auf freerealtime.com unter Kürzel: xzl bereits
0,19$zu sehen!!!
In Berlin wird schon zu 0,2€. getaxt, Frankfurt taxt 0,15€. im ask, es gibt aber dafür leider scheinbar keine...
Letzte Meldung schon sehr positiv:
Select Therapeutics Inc. Receives Notification of American Stock Exchange Acceptance of Plan of Compliance
BOSTON, Aug 1, 2002 /PRNewswire-FirstCall via COMTEX/ -- Select Therapeutics
Inc. (Amex: XZL), today announced that the American Stock Exchange ("AMEX" or
the "Exchange" has accepted Select`s plan of compliance and that the Company
has received a listing extension to regain compliance with AMEX`s listing
standards on or before December 31, 2003, subject to periodic review by the
Exchange.
On April 26, 2002, Select received notice from the AMEX Staff indicating that,
as of the date of the letter, the Company had fallen below the continued
listings standards of the Exchange due to stockholders equity below $2 million
dollars and sustained losses in two of its most recent fiscal years, as set
forth in Section 1003(a) of the AMEX Company Guide. Select was afforded the
opportunity to submit a plan of compliance to the Exchange and on May 28, 2002
the Company presented its plan to the Exchange. On July 26, 2002, the Exchange
notified Select that it accepted the Company`s plan of compliance and granted
the Company an extension of time to regain compliance with the continued listing
standards. Select will be subject to periodic review by Exchange Staff during
the extension period. Failure to make progress consistent with the plan or to
regain compliance with the continued listing standards by the end of the
extension period could result in the Company being delisted from the American
Stock Exchange.
"We are pleased to have received this notice of extension from AMEX," said Craig
Sibley, President and CEO. "This is another positive step forward in returning
Select to a stable and progressive status."
About Select:
Select Therapeutics Inc. is a drug development company engaged in the
development of novel, targeted therapeutic entities for the treatment of cancers
and infectious diseases. The Company is developing its proprietary, targeted
cancer therapeutic agent, VeroPulse(TM), for the treatment of certain cancers,
and also its proprietary targeted therapeutic vaccine technologies (Activate(TM)
and VeroVax(TM) for the treatment of cancers and infectious diseases. In
December 2001, Select Therapeutics Inc. terminated its joint venture, Cell
Science Therapeutics, and resumed an independent path for corporate and
technological development.
Certain of the statements contained in this news release may be considered
forward-looking statements. To the extent that any of the statements contained
herein are forward-looking, such statements are based on current expectations
and are subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. We caution investors that there can be no assurance that actual
results or business conditions will not differ materially from those projected
or suggested in such forward-looking statements as a result of various factors,
including, but not limited to, Select`s need for and ability to obtain
additional capital, the possible impairment of, or inability to obtain,
intellectual property rights and the cost of obtaining such rights from third
parties and dependence on third parties to research, develop, manufacture and
sell any products developed.
Was denkt Ihr?
MfG
Star Ikone 2
